MARKET

MDXG

MDXG

MIMEDX GROUP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.54
-0.07
-1.06%
Closed 17:11 11/23 EST
OPEN
6.65
PREV CLOSE
6.61
HIGH
7.00
LOW
6.44
VOLUME
389.55K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
2.950
MARKET CAP
726.24M
P/E (TTM)
-9.7307
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
MiMedx To Host Virtual 2020 Annual Meeting of Shareholders on Friday, November 20
MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided additional information about its upcoming virtual 2020 Annual Meeting of Shareholders (“Annual Meeting”). Timothy R. Wright, Chief Executive Officer, is scheduled to present an overview of the Company, and Rohit Kashyap, Ph.D., Executive Vice President and Chief Commercial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, are scheduled to present an overview of the Company’s commercial and R&D initiatives. Additional members of senior management also plan to be available for a question and answer session from shareholders as of the record date of 5:00 p.m. Eastern Time on October 7, 2020. Guests may join the virtual 2020 Annual Meeting, including the shareholder question and answer session, in a listen-only mode without a control number. The meeting is scheduled to be held on Friday, November 20, 2020 at 10:00 a.m. Eastern Time and will be conducted in a virtual format only in light of public health concerns regarding the coronavirus (COVID-19) outbreak.To participate in the virtual Annual Meeting, shareholders must visit www.virtualshareholdermeeting.com/MDXG2020 on Friday, November 20, 2020 and enter the 16-digit control number found on their proxy materials or voting instruction form. Please log in at least 15 minutes before the Annual Meeting begins to ensure ample time to complete the check-in procedures and test your computer audio system. Presentation materials will be posted on the Webcasts & Presentations section of the Company’s website immediately prior to the start of the meeting.The Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) and has mailed it with an accompanying proxy card for the virtual 2020 Annual Meeting to its shareholders. A free copy of the Proxy Statement and other relevant documents that the Company files with the SEC may be obtained through the SEC’s website at www.sec.gov or on the Company’s website at www.mimedx.com.About MiMedx MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.Contact Hilary Dixon Investor Relations & Corporate Communications 770.651.9066 investorrelations@mimedx.com
GlobeNewswire · 11/13 13:00
MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum
MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time. A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link below.Date: Thursday, November 19, 2020 Time: 9:30 AM ET Webcast: https://wsw.com/webcast/canaccord44/mdxg/2454624 A replay of the webcast will be available for approximately 45 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.About MiMedx MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.Contact Hilary Dixon Investor Relations & Corporate Communications 770.651.9066 investorrelations@mimedx.com
GlobeNewswire · 11/12 13:00
MiMedx Group reports Q3 results
MiMedx Group (MDXG): Q3 GAAP EPS of -$0.48.Revenue of $64.3M (-27.6% Y/Y)Non-GAAP Revenue of $63.26M (-6.3% Y/Y).Press Release
Seekingalpha · 11/04 21:20
MiMedx to commence trading on Nasdaq on November 4
MiMedx (MDXG) to commence trading on Nasdaq on November 4, 2020, under the ticker symbol “MDXG”. Source: Press Release
Seekingalpha · 11/03 22:36
MiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020
MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today confirmed that the Company’s common stock will commence trading on The Nasdaq Stock Market at the opening of trading on Wednesday, November 4, 2020, under the ticker symbol “MDXG”.About MiMedxMiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.ContactHilary Dixon Investor Relations & Corporate Communications 770.651.9066 investorrelations@mimedx.com
GlobeNewswire · 11/03 22:30
Largest U.S. payor to cover MiMedx's EpiFix for diabetic foot ulcers
MiMedx Group (MDXG) announces that the largest U.S. commercial payor will cover its EpiFix tissue product for the treatment of diabetic foot ulcers effective December 1.Beleaguered longs are hoping the
Seekingalpha · 11/03 13:15
MiMedx sees Q3 sales as high as $64M
On a preliminary basis, MiMedx Group (MDXG) expects Q3 sales of $61M - 64M, down 28 - 31% from a year ago although the Q3 2019 sales included a $21.5M
Seekingalpha · 09/21 10:36
MiMedx expects Q3 net sales of $61M-$64M
MiMedx (MDXG) expects Q3 net sales of $61M-$64M down from $88.9M in 3Q19. 3Q19 $88.9M sales include a benefit of $21.5M resulting from a change in the Company’s methods for
Seekingalpha · 09/21 10:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDXG. Analyze the recent business situations of MIMEDX GROUP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDXG stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 9.06M
% Owned: 8.16%
Shares Outstanding: 111.05M
TypeInstitutionsShares
Increased
0
0
New
2
134.14K
Decreased
5
123.31K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.12%
Healthcare Equipment & Supplies
-0.37%
Key Executives
Chairman/Independent Director
M. Kathleen Behrens Wilsey
Chief Executive Officer/Director
Timothy Wright
Chief Financial Officer
Peter Carlson
Executive Vice President
Rohit Kashyap
Executive Vice President
Robert Stein
Senior Vice President/Chief Accounting Officer
William Phelan
Senior Vice President
Scott Turner
Chief Compliance Officer
Mark Graves
General Counsel/Secretary
William Hulse
Director
Charles Koob
Independent Director
James Bierman
Independent Director
Charles Evans
Independent Director
William Hawkins
Independent Director
K. Todd Newton
Independent Director
Martin Sutter
Independent Director
Neil Yeston
Independent Director
M. Behrens Wilsey
Independent Director
J. Dewberry
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MDXG
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MiMedx Group Inc stock information, including NASDAQ:MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.